Premium
Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure
Author(s) -
Lemesle Gilles,
Chouraki Vincent,
de Groote Pascal,
Turkieh Annie,
Beseme Olivia,
Drobecq Hervé,
Amouyel Philippe,
Lamblin Nicolas,
Bauters Christophe,
Pinet Florence
Publication year - 2020
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.202000035
Subject(s) - medicine , heart failure , apolipoprotein b , etiology , pathophysiology , cardiology , cause of death , bioinformatics , oncology , cholesterol , disease , biology
Purpose Risk stratification in chronic systolic heart failure (HF) is critical to identify the patients who may benefit from advanced therapies. It is aimed at identifying new biomarkers to improve prognosis evaluation and help to better understand HF physiopathology. Experimental design Prognostic evaluation is performed in 198 patients with chronic systolic HF: 99 patients who died from cardiovascular cause within three years are individually matched for age, sex, and HF etiology (ischemic vs not) with 99 patients who are alive after three years of HF evaluation. A proteomic profiling of 15 apolipoproteins (Apo) is performed: Apo‐A1, ‐A2, ‐A4, ‐B100, ‐C1, ‐C2, ‐C3, ‐C4, ‐D, ‐E, ‐F, ‐H, ‐J, ‐L1, and ‐M using LC‐MRM‐MS. Results In univariate analysis, the levels of Apo‐B100 and ‐L1 are significantly lower and the levels of Apo‐C1, ‐J, and ‐M are significantly higher in patients who died from cardiovascular cause as compared with patients alive. In the final statistical model, Apo‐C1, Apo‐J, and Apo‐M improve individually the prediction of cardiovascular death. Ingenuity pathway analysis indicates these three Apo in a network associated with lipid metabolism, atherosclerosis signaling, and retinoid X receptor activation. Conclusions Proteomic profiling of apolipoproteins using LC‐MRM‐MS might be useful in clinical practice for risk stratification of HF patients.